Get the Stockscreener App
4.545
10.85%
0.445
Briacell Therapeutics Corp stock is traded at $4.545, with a volume of 350.74K.
It is up +10.85% in the last 24 hours and down -52.71% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$4.10
Open:
$4.04
24h Volume:
350.74K
Relative Volume:
1.08
Market Cap:
$12.45M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-5.1067
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-22.97%
1M Performance:
-52.71%
6M Performance:
-52.13%
1Y Performance:
-92.29%
1-Day Range:
$4.04
$4.65
1-Week Range:
$3.9201
$7.87
52-Week Range:
$3.9201
$65.25
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
4.545 | 12.45M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.97 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
706.12 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.65 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.74 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.03 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
HC Wainwright Has Positive Estimate for TSE:BCT Q2 Earnings - MarketBeat
United Therapeutics president sells $3.5m in stock - MSN
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism - MSN
H.C. Wainwright raises Briacell stock target to $32 on trial success - Investing.com
BriaCell announces public offering of common shares - MSN
BriaCell Therapeutics (NASDAQ:BCTX) Given New $32.00 Price Target at HC Wainwright - Defense World
BriaCell announces public offering of common shares By Investing.com - Investing.com South Africa
BriaCell Therapeutics slumps 20%, prices $3M stock offering - MSN
BriaCell Therapeutics Announces $3.05 Million Public Offering - TipRanks
Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each -February 03, 2025 at 08:04 pm EST - Marketscreener.com
BriaCell's $3.05M Capital Raise: Strategic Move or Dilution Concern? - StockTitan
BriaCell Therapeutics stock rises on positive clinical trial results - MSN
BriaCell Therapeutics Announces Pricing of Public Offering - GlobeNewswire
Wavelo Secures Four-Year Contract Renewal with EchoStar - The Globe and Mail
Briacell Therapeutics Announces Proposed Public Offering Of Common Shares -February 03, 2025 at 05:36 pm EST - Marketscreener.com
BriaCell Therapeutics Shares Hit Record Low After Public Offering News - MarketWatch
BriaCell Therapeutics Announces Public Offering to Fuel Growth - TipRanks
BriaCell Therapeutics Corp (BCTX) Stock: Navigating Drops and Gains - The InvestChronicle
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares - GlobeNewswire
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares - Benzinga
Cancer Immunotherapy Pioneer BriaCell Launches Strategic Funding Round for Next-Gen Treatments - StockTitan
Will BriaCell Therapeutics Corp (BCTX) meet earnings estimates this quarter? - US Post News
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Opt - Asianet Newsable
Promising Results and Strategic Expansion Underpin Buy Rating for BriaCell Therapeutics - TipRanks
BriaCell immunotherapy destroys metastatic breast cancer tumor | 2025-02-03 | Investing News - Stockhouse Publishing
BriaCell’s Bria-OTS™ Shows Promising Results in Resolving Breast Cancer Lung Metastasis - TipRanks
BriaCell announces resolution of lung metastasis in patient receiving Bria-OTS - TipRanks
BriaCell Therapeutics stock rises on positive clinical trial results By Investing.com - Investing.com UK
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™ - Markets Insider
BriaCell Therapeutics (BCTX) Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS - StreetInsider.com
Breakthrough in Breast Cancer Treatment: Patient's Lung Metastasis Vanishes After Novel Immunotherapy - StockTitan
1-800-FLOWERS (FLWS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Down 2.3% – Here’s What Happened - Defense World
BriaCell Announces Completion of 15:1 Share Consolidation - GlobeNewswire
BriaCell Completes 15:1 Share Consolidation for Nasdaq Compliance - TipRanks
BriaCell's Major Stock Transformation: 44M Shares Become 2.9M in Critical Nasdaq Move - StockTitan
BriaCell Therapeutics (NASDAQ:BCTXW) Shares Down 11.4% – Here’s Why - Defense World
5 AI Stocks to Load Up On in 2025 - The Globe and Mail
Why Truist Analysts Think Nvidia Stock Can Gain Another 50% in 2025 - The Globe and Mail
BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th - Defense World
Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 10-JAN-2025. - Marketscreener.com
BriaCell Therapeutics (CVE:BCT) Stock Price Down 3.8% – Here’s Why - Defense World
BCTX stock touches 52-week low at $0.46 amid sharp annual decline - Investing.com
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Up 2.7% – Here’s Why - Defense World
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - The Manila Times
BriaCell Announces Proposed Effective Date of Share Consolidation - The Manila Times
BriaCell Announces 15:1 Share Consolidation to Maintain Nasdaq Listing Compliance - StockTitan
Bullish BriaCell Therapeutics Insider Buying Worth US$5.52m Yet To Pay Off - Simply Wall St
Insider Purchases Worth US$5.52m See Losses As BriaCell Therapeutics Market Value Drops To CA$40m - Yahoo Finance
BCTXBriacell Therapeutics Corp. Common Shares Latest Stock News & Market Updates - StockTitan
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures - GlobeNewswire
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):